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A B S T R A C T
Atopic dermatitis is a chronic, relapsing, non-contiguous, exudative eczema/dermatitis, which represents a
complex, multi-factorial disorder, due to an impairment of the stratum corneum barrier. Currently available drugs
have a low skin bioavailability and may give rise to severe adverse events. Nanotechnologies, including nano-
particles, liposomes, nano-gels, nano-mixtures, nano-emulsions and other nano-carriers, offer unprecedented
solutions to these issues, enabling: i) the management of different clinical forms of atopic dermatitis, especially
the recalcitrant ones, i) a better bio-availability and trans-dermal drug targeted delivery at the inflammation site,
ii) dose control, iii) significant improvements both in clinical symptoms and immune responses, iv) with less
adverse events being reported and a better safety profile. However, some nano-sized structures could amplify
and even worsen symptoms in particularly susceptible individuals. Furthermore, most studies included in the
present systematic review have been conducted in-vitro or in-vivo, with few randomized controlled clinical trials
(RCTs). Future investigations should adopt this design in order to enable scholars achieving robust findings and
evidence. Therefore, given the above-mentioned shortcomings, further research in the field is urgently war-
ranted.
1. Atopic dermatitis: physiopathology and burden
Atopic dermatitis is a chronic, relapsing, non-contiguous, exudative
eczema/dermatitis, which represents a complex, multi-factorial dis-
order, due to an impairment of the stratum corneum barrier [1–3]. This
results in a disturbed skin function and an increase in trans-epidermal
water loss (TEWL), which leads to dehydration, and in a series of in-
flammatory processes characterized by the production and release of
several cytokines, chemokines and interleukins (including interleukin
type 1 beta or IL-1β, IL-4, IL-5, IL-6, IL-8, IL10, IL-12p70, IL-13, IL-17
and IL-17A, IL-19, IL-33 and thymic stromal lymphopoietin, or TSLP)
[4,5].
These molecules and others, such as tumor necrosis factor-alpha or
TNF-α and interferon-γ or IFN-γ, promote lipogenesis, activating lipids
that play a major role in the skin barrier but also in delivering bio-
chemical signals, which, in its turn, increases inflammation levels and
the risk of infections.
Atopic dermatitis is also characterized by alterations in the apop-
totic cascades [6]. Furthermore, an excessive amount of elastase in
peripheral blood neutrophils creates an imbalance between the con-
centrations of the proteolytic enzyme and its endogenous inhibitors and
leads to disrupted elastic fiber organization [7–9].
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Summarizing, despite being not still fully understood, atopic der-
matitis is traditionally regarded as a T helper type 2 lymphocytes-(TH2)-
mediated disease, whilst, recently, advancements in the field of basic
science have revealed that some other immune actors may play a cru-
cial role, like T helper type 17 lymphocytes (TH17) and T helper type 22
lymphocytes (TH22), as well as eosinophils and mast cells that de-
granulate contributing to the inflammatory microenvironment [10].
From a clinical standpoint, patients suffering from atopic dermatitis
complain of dryness, erythema, scaling and fissuring [1,2]. Atopic
dermatitis may occur anytime during life but its onset and development
should be regarded in the contest of “atopic march”; the series of events
that start from the skin and may affect mainly the respiratory system
(with disorders such as rhinitis, asthma, sinusitis) and eye (con-
junctivitis) [11].
Current management of atopic dermatitis comprises cyclosporine A,
topical calcineurin inhibitors (tacrolimus and pimecrolimus), and cor-
ticosteroids (that can be administered in a systemic or topical way).
Only recently atopic dermatitis has started to benefit from targeted
therapy, due to the advent of dupilumab, an anti-IL4/13 biologic, that
is capable to effectively solve also the patients resistant to systemic
treatments [12,13].
Synergically with the revolution in the treatment and management
of atopic dermatitis, clinicians have started to distinguish and better
study the late-onset atopic dermatitis that typically is more pleo-
morphic and less recognized, deserving a more accurate differential
diagnosis [14,15]. Each patient is different, in terms of prognosis,
burden of co-morbidities [16], and contraindications to the conven-
tional systemic treatments (hepatic or renal) or even to targeted
therapy (ocular disorders). Nanotechnologies, taking into account these
aspects, can pave the way to an individualized treatment and man-
agement of atopic dermatitis patients, in that drug delivery, controlled
release, dosage and skin permeation/retention play a key role [17].
2. Nanotechnology meets atopic dermatitis: current solutions
Nanotechnology-based therapeutics [18,19], including nano-
particles, nanogels, nanomixtures, nanoemulsions and other nano-
carriers, have been explored as potential treatments for atopic derma-
titis.
In this review, we have systematically searched PubMed/MEDLINE
mining its entire content since inception, without any time or language
constraint, utilizing the following string of key-words: (nanocarrier OR
nanocarriers OR nanotube OR nanotubes OR nanogel OR nanogels OR
nanoemulsion OR nanoemulsions OR nanostructure OR nanostructures
OR nanostructured OR nanosize OR nanosized OR nanovector OR na-
novectors OR nanocapsule OR nanocapsules OR nanoencapsulation OR
nanoencapsulated OR liposome OR liposomes OR cubosome OR cubo-
somes OR nanovesicle OR nanovesicles OR transfersome OR transfer-
somes OR nanotechnology OR nanotechnologies OR nanobiotechnology
OR nanobiotechnologies OR nanotherapeutics OR nanoformulation OR
nanoformulations OR nanovehicle OR nanovehicles OR nanodrug OR
nanodrugs OR nanodelivery OR nanocosmetic OR nanocosmetics OR
nanocosmeceuticals OR nanoshell OR nanoshells) AND (“atopic der-
matitis” OR “atopic eczema”). Medical subject headings (MeSH) terms
and wild-card (i.e., truncated words) options, were used where appro-
priate.
The working team was multi-disciplinary, comprising of two experts
in dermatology (G.D. and P.D.M.P.), an expert in research methodology
(N.L.B.) and an expert in biophysics and nanotechnology (R.E.). We
followed the “Preferred Reporting Items for Systematic Reviews and
Meta-Analyses” (PRISMA) guidelines [20]. Studies conducted in ani-
mals for veterinary purposes, being out of scope for the present review,
Fig. 1. Literature search strategy adopted in the present systematic review.
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were excluded [21–24]. Review articles, if existing, were scanned for
increasing the chance of getting potentially relevant articles but were
excluded from the present review. Extensive, iterative cross-referencing
was performed, checking the list of references of each eligible study
until no new study could be found. Further details are pictorially shown
in Fig. 1.
Nano-sized formulations found are described in the following
paragraphs.
3. Atopic dermatitis, nanoparticles and nanocarriers
Nanoparticles and nanocarriers seem to have optimal rheological
properties, antimicrobial effects and capability to restore skin condi-
tions. These nanostructures, such as silver (Ag-NPs) and silver-lipid or
poly(lactic acid) (PLA-NPs) nanoparticles [25–29] appear promising in
the treatment and management of patients with atopic dermatitis.
Pandey and coworkers [30] fabricated hyaluronic acid-decorated
betamethasone valerate-loaded chitosan nanoparticles (BMV-HA-CNPs,
nano-size of 300 ± 28 nm, positively charged zeta potential of 58 ±
8 mV, entrapment efficiency of 86 ± 5.6% and loading capacity of
34 ± 7.2%. Drug diffusion and permeation efficiency profiles ap-
peared to be optimal and promising for atopic dermatitis management.
Rosado and colleagues [31] fabricated hydrocortisone-loaded poly
(ε-caprolactone) nanoparticles (PCL-NPs) by modified solvent dis-
placement method, reporting good physical-chemical properties.
Kim and collaborators [32] evaluated the efficacy of cyclosporin A-
loaded solid lipid nanoparticles (CsA-SLN) prepared by hot homo-
genization method (size approximately of 73 nm, negative surface
charge of −16 mV). The product was tested in murine models, dis-
playing a 2-fold higher skin penetration and reducing the production
and release of IL-4 and IL-5 by T helper type 2 (TH2) lymphocytes.
Kang and coauthors [33] evaluated thermosensitive, solid lipid
nanoparticles loaded with tacrolimus (TCR-SLNs), comparing its effi-
cacy versus 0.1% Protopic® in a murine model. TCR-SLNs proved ef-
fective in drug delivery, allowing tacrolimus to reach the deepest skin
layers.
Singh and Pople [34–36] fabricated tacrolimus-loaded lipid nano-
particles by high pressure homogenization technique. Statistically sig-
nificant better drug controlled release and skin permeating profiles
could be found with respect to the reference ointment, Protopic®. Im-
mune responses were inhibited by 3.5 times, with fewer adverse events
reported.
Zhuo and colleagues [37] developed hyaluronic acid-decorated ta-
crolimus-loaded nanoparticles (HA-TCS-CS-NPs) and tested them in-
vitro. Drug release kinetics, permeation and efficacy were proved to be
satisfactory.
Yu and coworkers [38] assessed the feasibility of exploiting chit-
osan-based nanoparticles loaded with tacrolimus and combined with
nicotinamide (FK506-NIC-CS-NPs), in order to mitigate or counteract
the insurgence of adverse effects associated with high doses of FK506,
potentially occurring during long-term treatment. The formulation was
tested in animal models (BALB/c mice with 1-chloro-2, 4-dini-
trobenzene (DNCB)-induced atopic dermatitis). FK506-NIC-CS-NPs
based formulation was compared with a commercially available oint-
ment (Protopic®). Delivery and permeation of FK506 was increased up
to 92.2%, enabling to spare dose of FK506.
Siddique and coauthors [39–41] exploited nanoparticles for a tar-
geted delivery of systemic corticosteroids at the inflammation site. In a
murine model, topically applied cationic polymeric chitosan-based
nanoparticles (CSNPs) loaded with anti-inflammatory hydrocortisone
and antimicrobial hydroxytyrosol (HC-HT-CSNPs, size of
228.5 ± 7 nm and positive surface charge of 39± 5 mV) displayed
optimal epidermal and dermal permeation, reaching the deepest skin
layers with an efficiency 2.46-fold higher with respect to the com-
mercial reference formulation. No evidence of toxicity could be found.
Similarly, Hussain et al. [42–44] explored the effects of
hydrocortisone-loaded chitosan-based nanoparticles (HC-CNPs) in a
model of 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/
Nga mice. HC-NPs resulted in down-regulated inflammatory cascades
(reduced production of IgE, IL-4, IL-5, IL-6, IL-13, IL-12p70, IFN-γ, TNF-
α. release of histamine, expression of prostaglandin-E2 and vascular
endothelial growth factor-α, VEGF- α), in the sera and skin. At a cellular
level, events such as fibroblast infiltration and fragmentation of elastic
fibers were inhibited or drastically reduced.
Huang and collaborators [45] fabricated 7,3′,4′-trihydroxyiso-
flavone based nanoparticles by planetary ball mill preparation under a
solvent-free process (734THIN) using polyvinylpyrrolidone K30 as ex-
cipient. This formulation inhibited the expression of COX-2 and MMP-9
by down-regulating the “Mitogen-Activated Protein Kinase” (MAPK)-
related signaling cascade.
Dessy and coworkers [46] prepared polymeric nano-particles based
formulations loaded with anti-inflammatory Dead Sea Water (DSW)
minerals (calcium, magnesium, sodium, potassium, zinc and stron-
tium). Nanoparticles consisted of Poly (maleic anhydride-alt-butyl vinyl
ether) 5% grafted with monomethoxy poly(ethyleneglycol) 2000 MW
(PEG) and 95% grafted with 2-methoxyethanol (VAM41-PEG), pre-
pared using a combined mini-emulsion/solvent evaporation process,
and had a nano-size of 300 nm. Drug delivery and release properties
were found to be satisfactory.
Nagaich and Gulati [47] fabricated nanocarriers loaded with beta-
methasone valerate, which demonstrated a permeation profile 2.59
folds higher than commercially available betamethasone valerate gel
and an extended anti-inflammatory effect (up to 16.5%).
Finally, Tessema and collaborators [48] fabricated nano-carriers
loaded with oat-derived phytoceramides, including lecithin-based mi-
croemulsions and starch-based nanoparticles, using Carbopol®980 as a
gel. The delivery system demonstrated appropriate physical-chemical
properties.
4. Nano-capsules
Marto and coworkers [49] explored the feasibility of topically de-
livering a novel synthetic human neutrophil elastase inhibitor (ER143)
by means of a starch-based nanoparticulate system (StNC), demon-
strating good permeation and retention profiles.
MD and colleagues [50] developed an ad hoc nano-encapsulated
delivery system for atopic dermatitis: chitosan nanoparticles loaded
with betamethsone valerate (BMV-CS-NPs, nano-size of 250 ± 28 nm,
positively charged zeta potential of 58 ± 8 mV). The formulation
showed satisfactory entrapment efficiency and loading capacity.
5. Lipid nano-mixtures and nano-emulsions
Berardesca and coworkers [51] assessed the effectiveness of a to-
pical skin lipid mixture containing ceramide-3 and nanoparticles alone
or combined with topical corticosteroids administered until clearance
or for a period of 8 weeks. Authors found improvements both in terms
of skin physiology and barrier properties and clinical symptoms.
Yilmaz and Borchert [52] investigated the efficacy of positively
charged oil/water nano-emulsions (PN) containing ceramide-3B and
ceramide-3, cholesterol, and palmitic acid (PNSC). Creams of PNSC
were compared to PN, negatively charged oil/water nano-emulsion and
SC lipids (NNSC) prepared by high-pressure homogenization and sta-
bilized with a thickener (Carbopol-940) and a commercially available
cream (Physiogel®). Each formulation was tested in a sample of 14
healthy females aged 25–50 years. All products were found to increase
skin properties in terms of hydration and elasticity, with PNSC being
significantly more effective than PN and NNSC, suggesting a role of
phytosphingosine, lipids and ceramides.
Similarly, Neubert and coworkers [53] compared different nano-
formulations: a colloidal microemulsion based of novel dimeric cer-
amides, a ceramides-based cream with ethoxydiglycol as penetration
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enhancer and a nano-formulation, finding that the former had the
lowest penetration and permeation profiles, whilst the use of a pene-
tration enhancer significantly improved the physical-chemical proper-
ties of the drug.
Bernardi et al. [54] assessed the effectiveness of rice bran oil nano-
emulsions (10% rice bran oil, 10% surfactants sorbitan oleate/PEG-30
castor oil, 0.05% anti-oxidant and 0.50% preservatives formulated in
distilled water) utilizing low energy emulsification methods, such as the
phase diagram method. The product was found to be stable, displaying
a low irritation potential, improving skin moisture and maintaining pH
values within its normal range.
Baspinar and coauthors [55,56] prepared positively charged pre-
dnicarbate nanoemulsions using high pressure homogenization method.
The formulation was found to be stable and potentially adequate for the
treatment and management of atopic dermatitis patients.
Verma and Fahr [57] utilized a lipid mixture, NAT-8539, to enhance
the topical delivery of cyclosporin A (NAT-8539-CyA), with vesicles in
the range 56.6–100.6 nm of diameter and ethanol between 10% and
20%. Depending on the concentration of ethanol and the nano-size of
vesicles, the nano-mixture proved to be effective in reaching the dee-
pest skin layers.
Finally, Espinoza and colleagues [58] improved the delivery of
pioglitazone, a peroxisome proliferator-activated receptor agonist, by
fabricating a nano-emulsion (PGZ-NE). This formulation was proved to
decrease several inflammatory cytokines, such as IL-6, IL-1β and TNF-α.
6. Liposomes, nanoliposomes and nanovesicles
Due to skin barrier defects and impairment, the stratum spinosum
and stratum granulosum of atopic dermatitis patients appear to be rich in
lamellar, ovoid, membrane-coating granules (MCGs), comprising of
extruded, parallel disks that give rise to the formation of continuous
lamellae [59–63]. Being structurally similar, liposomes can be utilized
for the management of atopic dermatitis, with a hydrating effect on the
stratum corneum [63], as well as being able to act as carriers of bioactive
compounds [62,63].
The first pioneering study to investigate the effects of a liposomal
preparation dates back to the nineties. Korting et al. [64] used a beta-
methasone dipropionate (0.039%)-loaded liposome (BDP-liposome).
For this purpose, they recruited 10 patients in a double-blind, rando-
mized, paired trial and administered BDP-liposome for two weeks versus
a commercial propylene glycol-gel containing 0.064% beta-methasone
dipropionate. The liposomal preparation proved effective, significantly
reducing inflammation and erythema and scaling.
Based on these findings, Eroğlu and coworkers [65] prepared be-
tamethasone valerate/diflucortolone valerate-loaded chitosan-based
liposomes (nano-size of 220–350 nm), with the formulation proving to
be safe and effective in ameliorating atopic dermatitis symptoms in an
animal model.
Ibaraki and colleagues [66,67] explored the potential effects of a
topically delivered small interfering RNA (siRNA)-based treatment
using AT1002 combined with a flexible, highly permeable anti-nuclear
factor-kappa B (NF-κB) (RelA)-encapsulated 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine/cholesteryl hemisuccinate (siRelA-DOPE/
CHEMS) liposome. AT1002 was chosen in that is a peptide able to open
and finely modulate tight junctions [68,69]. The formulation was tested
in in-vitro and in-vivo (animal and human) models.
Another peptide which may be of interest for the treatment of atopic
dermatitis is Pep-1. Kang and coauthors [70] explored in a murine
model (NC/Nga mice) the effects of a peptide-conjugated elastic lipo-
somal formulation (comprising of phosphatidylcholine, Tween 80, N-
[4-(p-maleimidophenyl)butyryl]-phosphatidylethanolamine or MPB-
PE) of taxifolin glycoside (TXG-Pep1-EL, nano-size of 130 nm, zeta
potential of 25 mV and deformability index value of 60). Authors found
optimal skin delivery, permeation and retention profiles, as well as
improvements in skin properties in terms of hydration, elasticity and
immune responses.
Kang et al. [71] developed oregonin-loaded elastic, highly flexible
liposomes consisting of soybean phosphatidylcholine and Tween 80
(85:15 water/water %) (ORG-EL, nanosize of 130 nm and 4-fold greater
deformability index than conventional liposomes). Permeation prop-
erties of the nanocarriers were excellent and were further increased by
the addition of a peptide, Trans-activating transcriptional activator
(Tat), which can modulate and open tight junctions (ORG-EL-Tat).
Concentrations of inducible nitric oxide synthase (iNOS), cycloox-
ygenase-2 (COX-2), IL-4, IgE, and eosinophils in skin or blood were
found to be significantly reduced.
Tat peptide (0.16 water/water %) was utilized also to facilitate skin
delivery and permeation of a natural immune-modulator, hirsutenone,
by means of ad hoc devised liposomes consisting of phosphatidylcholine
and Tween 80 (85:15 water/water %) (HST-EL-Tat), prepared by thin-
film hydration method, in an investigation carried out by Kang and
coworkers [72]. Levels of iNOS, COX-2, IL-4, IL-13, IgE, and eosinophil
were decreased in a murine model.
Augustin and colleagues [73] tested the effectiveness and the anti-
septic, anti-inflammatory properties of liposomal polyvinyl-pyrrolidone
(PVP)-iodine (3%) hydrogel administered for up to 4 weeks in a pro-
spective, single-arm, uncontrolled, open-label phase II, pilot clinical
trial recruiting 20 patients with atopic dermatitis. The “Global Clinical
Severity” (GCS), pain, quality of life and “Eczema Area and Severity
Index” (EASI) scores significantly improved. Formulation was well
tolerated, with generally mild adverse events being reported.
Liposomes loaded with 18β-glycyrrhetinic acid, the major metabo-
lite of glycyrrhizin, extracted from licorice root, and characterized by
anti-microbial, anti-oxidative properties, appear to be another pro-
mising therapeutic solution for the management of atopic dermatitis
[74].
Jung and coauthors [75] improved the topical skin delivery of co-
balamin/vitamin B12 by preparing a liposomal hydrogel of adeno-
sylcobalamin (Lipo-AdCbl, nano-size of 106.4 ± 2.2 nm) by thin film
hydration method. Skin permeability was increased up to 17-times in a
murine model (NC/Nga mice) with ameliorated symptoms and immune
responses.
Goindi and coworkers [76,77] enhanced skin delivery of cetirizine/
levocetirizine dihydrochloride, a piperazine-derived second-generation
anti-histaminic drug, by combining Phospholipon®90G and edge acti-
vators. The formulation was found to have good penetration and per-
meation profiles in a murine model, significantly reducing dermal eo-
sinophil count, erythema and itching scores with respect to
conventional ointments and creams.
Liposomes can be utilized also for gene delivery. For instance, Kim
and collaborators [78] developed IL-13 antisense oligonucleotide
complexed with cationic elastic liposome (IL-13-ASO-cEL). The for-
mulation was able to suppress IL-13 production and release. by up to
70%, as well as IL-4 and IL-5.
Finally, liposomal formulations can as well act as carriers of stem
cells or purified extracts from stem cells, as in the investigation by Jahn
and colleagues [79]. Authors fabricated proliposomes consisting of soy
phosphatidyl choline, Poloxamer-407, ethanol and sorbitol, loaded with
advanced adipose stem cell derived protein extract (AAPE, nano-size of
589 ± 3.6 nm, negatively charged zeta potential of
51.33 ± 0.36 mV). Proliposomes were stable with good physical-
chemical properties.
7. Atopic dermatitis, ethosomes, nanoethosomes, cubosomes,
nanofibrils and other nanocomposites
Akhtar and colleagues [80] developed β-cylcoethosomes based on
β-cycloamylose and carbomer 934P gel (nano-size of
228.33 ± 1.23 nm), demonstrating good skin permeability, whereas Li
and coworkers [81,82] prepared ethosomes loaded with tacrolimus,
obtaining satisfactory pharmacological effects.
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Izumi et al. [83] assessed the effect of chitin nanofibrils (CNFs) in a
murine model. CNFs proved as effective as the topical application of
corticosteroids. From a molecular standpoint, CNFs seem to reduce NF-
κB, COX-2, iNOS, and IgE levels.
Kwon and Kim [84] fabricated lipid cubosomes, loaded with water-
soluble extracts of Houttuynia cordata and tested them in hairless mice.
The formulation was found to decrease IgE and IL-4 expression, while
stimulating IFN-γ expression.
Shershakova and coworkers [85] exploited water-soluble forms of
fullerene C60 prepared by exhaustive dialysis of water-organic C60
solution against water (nano-size of 100 nm and negatively charged
zeta-potential of 30 mV). In a murine model female BALB/c mice, im-
provements in immune responses (reduced concentrations of IgE and
TH2 cytokines, with increased levels of TH1 cytokines) and skin barrier
function (increased levels of Foxp3+ and filaggrin expression) were
detected.
8. Nanotechnology and atopic dermatitis: current challenges
Despite their hope and promises, nanotechnology-based solution
can have also triggering effect on the induction of allergic reactions and
the clinical amplification of such symptoms. Utilizing a mouse model,
Kang and collaborators [86] found that 5- but not 100-nm nano-sized
Ag-NPs induce release of granule from tryptase-positive mast cells, as
well as lead to increased reactive oxygen species (ROS, hydrogen per-
oxide and mitochondrial superoxide) levels and intracellular calcium
concentrations.
Similar adverse advents have been reported for titanium dioxide,
silica and zinc oxide-based nanoparticles [87–90].
However, a final consensus on the safety of nanotechnological de-
vices is yet to be established, needing more convincing investigations
that expert scientists should consider and appraise carefully. Further
research in this field is, therefore, warranted.
9. Future prospects
Nanotechnology-based therapeutics appear promising also in pre-
venting atopic dermatitis. Oral oligodeoxynucleotide nanocapsules
(iODN-CAPs/iSG3-CAPs) specifically targeting the gut Peyer's patches,
after being administered and taken up by macrophages, are able to
induce an effective immune response. If continuously administered,
iODN-CAPs/iSG3-CAPs in the long-term seem to display inhibitory/
suppressive effects, preventing the insurgence of skin lesions and re-
duced epidermal thickness and elasticity typical of atopic dermatitis.
From a molecular standpoint, this formulation binds to the “Signal
Transducer and Activator of Transcription 6” (STAT-6), inhibiting its
phosphorylation. STAT-6 gene is involved in the etiopathogenesis of
atopic dermatitis, increasing its propensity and risk, leading to dis-
seminated viral infections [91]. Signaling pathways and IL-4 related
cascades, that are usually mediated by binding of allergens to TH2 cells
or environmental stimuli, are, therefore, inhibited.
Finally, most studies included in the present systematic review have
been conducted in-vitro or in-vivo, with few randomized controlled
clinical trials (RCTs). Future investigations should adopt this design in
order to enable scholars achieving robust findings and evidence.
10. Conclusions
Nanotechnology-based solutions appear promising in the manage-
ment of atopic dermatitis, especially the recalcitrant forms, enabling: i)
a better bio-availability and trans-dermal drug targeted delivery at the
inflammation site, displaying better physical-chemical properties, per-
meation, retention and diffusion profiles, ii) dose control, iii) im-
provements both in clinical symptoms and immune responses, in-
hibiting inflammatory cascades and pathways up to 3–5 times and
positively impacting on patient's quality of life, iv) with less adverse
events being reported [92–99].
However, given the above-mentioned shortcomings, further re-
search in the field is urgently warranted.
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